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Abstract 
Purpose:  To report our experience with dexamethasone intravitreal implant (Ozurdex, DEX implant) in the chronic cystic macular 
edema (ME )with  Vogt-Koyanagi-Harada (VKH) Syndrome. 
Method: A retrospective chart review of three patients with (VKH)  treated  with sustained-release dexamethasone 0.7 mg 
intravitreal implant was performed.Complete ophthalmic examination included:  best corrected visual acuity; ocular tonometry,   
were also evaluated signs of inflammatory activity of the anterior segment with biomicroscopy slit-lamp, and posterior segment with 
fundus biomiocrosopy, fundus photography and fluorescein angiography; measurement of macular morphology and thickness,  optical 
with coherence tomography;  and tolerability of the implant. Mean follow-up time post-injection was 6 months. All three eyes 
received 1Ozurdex implants  during the follow-up period. The duration of effect of the implant was 4 to 6 months. No serious ocular 
or systemic adverse events were noted during the follow-up period. 
Results:  In all three eyes,  were observed a remarkable decrease ME,  in angiographic and OCT , following placement  intravitreal 
DEX implant 
Conclusions: The DEX implant 0.7 mg may be an effective treatment option for  reduction   ME in VGT, met the primary efficacy 
endpoint for improvement in visual acuity (VA) and   safety profile was also acceptable 
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Introduction 
VKH is often associated with neurological and 
dermatological manifestations and affects organs 
containing melanocytes, whose etiology is still uncertain 
[1]. It would appear that a viral antigen is involved, 
against which, in individuals with certain predisposing 
haplotypes, it would cause an autoimmune reaction [2]. 
The inflammatory reaction is directed against a stromal 
protein present in the melanocytes and against neuronal 
elements. The disease affects both eyes, although 
asymmetrically, and it has a progressive evolution. The 
symptomatology consists of:  reduction of visual acuity, 
visual field reduction, metamorphopsia, floaters, alteration 
in color vision. In the acute phase, but more frequently in 
the convalescent phase and in the chronic phase [3]. 
It observed  an involvement inflammatory of the 
anterior segment characterized by uveitis that cause 
redness, pain and further AV reduction [4].  
Clinically it is possible to identify four stages of the 
disease: 1 prodromal: (3–5 days maximum) characterized 
by headaches, dizziness and nausea accompanied by a flu-
like syndrome2 Acute exudative uveitis : appears with 
auditory and meningeal symptoms and can occur acutely 
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with severe iridocyclitis and ear involvement [5]. The 
acute exudative uveitis shows corneal precipitates in ram 
fat, cells and flare in the aqueous humor, irises nodules 
and synechiae. The severe manifestations charged to the 
posterior segment are: vitritis, edema and hyperemia of the 
optic disc, macular edema, chorioretinal scars, bleeding 
and choroiditis with exudative retinal detachment chronic: 
it may occur an increase of pigmentation or an albinotic 
depigmentation in those areas prior serous detachment, or 
even a fibrotic subretinal organization (typical appearance 
as "sunset flash") [3].  
 chronic with relapses: can be observed further 
complications such as cataracts, glaucoma, 
neovascularization and subretinal fibrosis.  Relapses occur 
in 60% of cases in the first four years and involve mainly 
the anterior segment. The long-term prognosis is 
unfavorable, as there is a final loss of central vision 
through the direct  
involvement retinal detachement and/or the 
maculopathy [2].  Daily administration of sistemical 
steroids,  if established prematurely, can delay the 
progression of the disease [3].  
Since some of the complications that are often 
connected with this disease, and which are able to further 
compromise the patient’s vision, are susceptible to 
treatment, it is good to subject patients to regular follow-
up with the aim of identifying any complications to treat 
them early.  
The complications that manifest themselves most 
frequently include the cataract e glaucoma, (common in 
all forms of VKH ; these are treatable) and the more 
serious maculopathy, ME, subretinal neovascularization. 
The latter may appear in atrophic form (cellophane 
maculopathy), or they may cause cystic macular edema, 
leading to the increased permeability of the perifoveal 
capillary network. For the latter form, good results can be 
obtained through systemic administration of steroids [6]  
The steroids represent so far the first choice about the 
uveo-encephalitis therapy and it need to be set as soon as 
possible and in the long term [4]. Nevertheless its 
effectiveness is still controversial. ME is often refractory to 
oral administration, intravenous and / or topical steroid 
therapy [6].  
Unfortunately, corticosteroid may notoriously lead to 
the onset of severe side effects [5].  That is the reason why 
the frequent and important side effects of corticosteroid  
do not allow it to be administered for a prolonged period 
of time  [6]. For this reason, it is necessary to find an 
alternative therapy that can be administered to these 
patients to prevent their visual acuity impairment, even 
before panuveitis, has run its course. Currently it seems 
that intravitreal injections of corticosteroids have shown to 
be effective in the treatment of chronic and relapsing 
forms of VKH [7].  
For this reason, we describe three case reports of 
patients treated with dexamethasone intravitreal implant,  
to date, has not shown any systemic secondary effects. In 
accordance with literature [5] we defined the primary 
endpoint  improvement BCVA and the secondary 
endpoint, significant improvement in the degree of ME, 
which was determined by measuring changes in the 
central foveal thickness and the foveal zone thickness on 
optical coherence tomography (OCT).  
 
Materials and Methods  
In this study, we report three cases of patients with 
VKH, successfully treated of DEX implant 0.7 mg  
(Ozurdex(®); Allergan, Inc, Irvine, CA) intravitreal  [5]. 
This study was conducted in compliance with the Ethics 
Committee of the Department of Organs Senses of the 
University of Rome “Sapienza” , all patients provided 
written, informed consent. A systemic work-up included 
laboratory and radiographic imaging for infectious and 
noninfectious etiologies.  Before initiating treatment, a 
baseline OCT scan was obtained on each patient with a 
Spectralis HRA-OCT produced by Heidelberg 
Engineering GmbH (Heidelberg, Germany) with a 
volumetric 512 × 49 scan for the measurement of macular 
thickness and morphology. The evaluation of vision was 
carried out pretherapy at baseline T0; best corrected VA 
was assessed using Early Treatment Diabetic Retinopathy 
Study (ETDRS) [8] tables placed at a distance of 4 meters, 
by slit-lamp biomicroscopy, ocular tonometry (using a 
Goldmann applanation tonometer), fundus 
biomiocroscopy, color fundus photography and 
fluorescein angiography. None of the patients in our study 
had additional ocular conditions or were on other 
medications that could potentially affect their visual acuity 
and/or retinal function. At subsequent follow-up visits, 
OCT images for all three patients were obtained. A central 
foveal thickness was calculated as an average of the 
measurements obtained. A change of more than 16% in 
foveal thickness and more than 11% in foveal zone 
thickness were considered significant. We compared all 
subsequent retinal thicknesses. It was performed 
fluorescein angiography (FA) and indocyanine green 
angiography (IGA) in order to highlight multiple sites of 
diffusion from the choroid into the subretinal space. After 
the first follow-up visit, each patient was seen several times 
(follow-up visits ranged from 2–6 months from the 
previous visit) to monitor the patient’s response to 
treatment. At each visit, a repeat OCT measurement was 
obtained.   
 
Results  
Case 1.   
A 52-year-old woman suffering from VKH disease, 
demonstrated microcystic macular edema on OCT, with a 
visual acuity of 4/10 in right eye (RE) and of 9/10 in left 
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eye (LE). She had a negative anamnesis of extraocular 
manifestations. The ocular anamnesis was negative for 
traumas, surgery and other diseases.  
 
 
 
 
 
 
 
Figure 1. A) Baseline optical coherence tomography (OCT) 
RE (Right eye) with cystoids macular edema (CME). B) RE 
after 2 week  following the 0.7 mg DEX implant intravitreal, 
OCT revealed a drastic reduction in CME. C)  6 months 
following implant placement OCT RE showed no recurrence 
of CME. 
 
She had a VA of 4/10 (29/65 ETDRS letters) in the 
RE and 9/10 (62/65 ETDRS letters) in the LE. There 
were no evident signs of anterior segment inflammation. 
The fundus oculi examination showed bilateral exudative 
retinal detachment and ME.  
The OCT examination showed the presence of intra- 
and subretinal fluid in both eyes. (See figure)  
The FA examination showed multiple leakage points and 
pooling areas. A 3-days intravenous methylprednisolone 
therapy (500 mg / day) was set; after that, improvements 
in visual acuity and retinal edema reduction occurred in 
both eyes. Subsequently, by switching from intravenous to 
oral therapy with prednisone (1 mg / kg for 4 weeks), a 
morpho-functional worsening occurred in both eyes.    
Therefore , in order to keep the edema under control, a 
DEX was set up in the RE  with worse BCVA. In further 
checkups, a progressive improvement in visual acuity and 
a tendential retinal edema reduction were observed; 
 
 
 
 
 
 
 
Figure 2. A) Baseline optical coherence tomography (OCT) 
LE  (Left eye) with cystoids macular edema (CME). 
B) LE after 2 week  following the 0.7 mg DEX implant 
intravitreal, OCT revealed a drastic reduction in CME. C)  
6 months following implant placement OCT LE  showed no 
recurrence of CME. 
 
 
this led to a reduction and a subsequent suspension of the 
oral therapy.  
During the follow-up, after six months from the injection, 
it was observed that the VA was corrected to 10/10 (65/65 
ETDRS letters) in RE e 9/10 (62/65 lettere ETDRS) in 
LE and that there was absence of intra- and sub-retinal 
fluid on OCT examination (CMT RE 276 µm, CMT LE 
355 micron). Furthermore, there weren't increases in 
intraocular pressure (IOP) (Fig.1). 
 
Case 2. 
A 35-year-old woman suffering from VKH presented 
with ME both eyes, as documented upon OCT, with a 
VA of 5/10 in RE and 3/10 in LE.   
The medical history was positive for an episode of 
bilateral anterior uveitis about 6 months before 
successfully treated with topical dexamethasone 0.2% 
(LUXAZONE ®). The initial BCVA resulted of 3/10  
   A 
   B 
  C 
   A 
   B 
   C 
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(25/65 ETDRS letters) in RE and 5/10 (47/65 ETDRS  
letters) in LE. At the time of our assessment there were no 
signs of inflammation of the anterior segment. The 
ophthalmoscope examination of fundus highlighted a 
macular edema, more evident in RE.  
The OCT examination confirmed the presence of 
cystoid macular edema (CME) (RE: CMT  455 µm, LE: 
311 µm CMT ). FA showed many leakage points and 
pooling areas. Therapy with oral prednisone (1 mg / kg 
for 4 weeks) does not show substantial improvement in 
terms nor morphological (evalued by OCT) nor 
functional.    
It was therefore decided to make an intravitreal  of 
DEX implant in the RE.   
After 6 months the patient showed considerable edema 
reduction in RE; her VA increased to 8/10 (8/10; 55/65 
lettere ETDRS) compared to the contralateral (5/10; 
45/65 lettere ETDRS) with considerable reduction of 
macular thickness observed with OCT (RE: CMT  291 
µm,  LE:  CMT  312 µm) (Fig. 2). 
 
Case 3.   
A 48-year-old woman suffering from VKH  presented 
with ME in both eyes, as documented by OCT at the 
beginning, at the first examination, she presented chronic 
anterior bilateral granulomatous uveitis, emerged two 
years before and then remained quiescent throughout the 
period. Had  a VA of 4/10 in OD (34/65 lettere ETDRS) 
e 3/10 (29/65 lettere ETDRS) in LE. The fundus 
examination was made difficult by endothelial 
precipitates.  
In topical therapy with topical dexamethasone 0.2% 
(LUXAZONE®) 6 times a day for 6 weeks..  
The not optimal VA was explained by the presence in 
both eyes of CME documented with OCT (RE: CMT 
317 µm, LE: CMT 344 µm) and with FA and, 
furthermore, LE showed a cataract advanced (N3C3P1). 
It was decided to make an intravitreal implant of DEX in  
the LE with a VA worse. In the third month of follow-up 
the patient is subjected to phacoemulsification operation 
to the LE with IOL implantation in the capsular bag, 
reaching after seven days a VA of 9/10 (62/65 ETDRS 
letters).   
This result coincided with the improvement of the 
CME documented by OCT (LE: CMT 292 µm). After 6 
months of follow-up, the patient presented again a 
lowering of VA (7/10, 48/65 ETDRS letters) in LE, 
explained by a new increase in macular thickness (RE: 
CMT 319 µm , LE: CMT 322 µm) due to  the presence 
of intraretinal fluid (CME).  
However the value of CMT in LE, six months after 
intravitreal implant DEX, did not reach the values of basal 
In RE the VA remained almost constant (5/10, 31/65 
ETDRS letters) (Fig.3). 
 
Discussion  
There are no codified, uniform guidelines for the 
treatment of clinically significant ME [9,11] Therefore,  
various therapeutic options have been considered [12-14].    
ME is one of the most important clinical disabling 
manifestations of ocular and in patients with VKH 
syndrome [1-4].  
Intravitreal treatment with corticosteroids 
undoubtedly plays a key role in the management of 
macular complications of an exudative nature [5].  
Byon [9] highlighted as triamcinolone acetonide is a 
valid treatment of ME for patients suffering from VKH  
in the acute phases and in short duration relapses  and as 
the need for repeated injections expose patients to a 
greater risk of endophthalmitis, increases in IOP and the 
onset of cataracts [15].  
 
 
 
 
 
 
 
Figure 3. A) Baseline optical coherence tomography (OCT) 
LE  (Left eye) with cystoids macular edema (CME). 
B) LE after 2 week  following the 0.7 mg DEX implant 
intravitreal, OCT revealed a drastic reduction in CME. C)  
6 months following implant placement OCT LE  showed no 
recurrence of CME. 
 
For this reason, a new intravitreal device with slow 
corticosteroid (dexamethasone) release has been 
developed, able to exercise a significant anti-edema action,  
   A 
   B 
   C 
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Table 1. Changes from baseline (T0) to the first follow-up visit within 3 months of starting therapy with DEX 
implant  (T1) and follow-up visit at 6 months (T2) in central macular thickness (CMT). 
 
Patients 
Number  
Gender Age  T0   CMT (Central 
Macular Thickness; 
microns)  
T1   CMT (Central 
Macular Thickness; 
microns) 
T2   CMT (Central 
Macular Thickness; 
microns)  
T3   CMT (Central 
Macular Thickness; 
microns)  
Eye      RE  LE  RE  LE  RE  LE  RE  LE  
A  F  52  432  352  296  355  285  358  276  355  
B  F  35  455  311  275  308  292  315  291  312  
C  F  48  317  344  317  288  319  292  319  322  
 
 
 
after being injected into the vitreous and able to 
maintain the integrity of the outer membrane, as well as of 
the inner one and outer segments of interface 
photoreceptors as documented by the OCT.  
The reduction of CMT generally results in an 
improvement in VA [13,14]. 
In the three tested patients, DEX intravitreal implant, 
has caused a significant reduction in their ME, as shown 
in the OCT [16, 17].  
This insert, for the edema treatment, could be used as  
 
 
 
 
 
maintenance therapy in the management of 'chronic ME. 
For this reason, the DEX intravitreal implant, approved 
by the FDA for treating macular post  
thrombotic edema [13,18] and macular noninfectious  
posterior uveitis edema , has undeniable advantages over 
other intravitreal corticosteroids, including: the 
biodegradability of the dexamethasone system compared 
to other implants, does not need to be removed, low cost 
[10] and less frequent giving with reduction of collateral 
effects [19] . 
  
 
Table 2. Changes from baseline (T0) to the first follow-up visit within 3 and 6 months of starting therapy with DEX 
implant  (T1) in Visual Acuity (ETDRS).
  
PatientsNumber Gender Age T0   BCVA 
(ETDRSLETTERS)  
T1   BCVA 
(ETDRSLETTERS) 
T2   BCVA 
(ETDRSLETTERS)  
T3   BCVA 
(ETDRSLETTERS) 
Eye    RE  LE  RE  LE  RE  LE  RE  LE  
A  F  52  29  62  52  59  57  60  65  62  
B  F  35  25  47  45  46  51  45  55  45  
C  F  48  40  30  43  44  42  62  44  31  
T0= PREOPERATIVE  
EVALUATIONT1= 1 MONTH AFTER OZURDEX  
T2=3 MONTHS AFTER OZURDEX  
T3=6 MONTHS AFTER OZURDEX  
 
 
Initial studies seem demonstrate the effectiveness of 
DEX intravitreal implant in controlling inflammation not 
only in the vitreous body but also at the level of the 
anterior segment. This result, in particular, has made it 
possible to suspend temporarily the topical  and systemic 
treatment steroids that these patients had to perform. 
However, intravitreal corticosteroids could play a role as 
adjuvant therapy. The small number of randomized 
double-blind clinical trials do not establish absolutely the 
greater effectiveness of DEX implant than other 
corticosteroids.  
However Hunter et al [12] reported greater efficacy of 
dexamethasone versus fluocinolone in terms of BCVA: the 
improvement of 15 ETDRS letters is achieved in 21% of 
patients treated with fluocinolone after 34 weeks and 38%  
 
 
 
 
 
after 26 weeks with dexamethasone. The randomized 
study carried out by Kupperman et [14] al using the 
implant of dexamethasone in the treatment of persistent 
ME detected a statistically significant improvement in VA  
after 90 days [12]. These data are in agreement with the 
result obtained in our cases, in which it is obtained a 
reduction of CMT resulting in improved VA  after 6 
months.  
Except for the patient subjected to 
phacoemulsification, the significant improvement of VA is 
due to the significant decrease in ME, as shown by the 
OCT examination in the three cases.  
The difference in half-life of dexamethasone compared to 
fluocinolone makes it difficult to compare the relative 
effectiveness in the absence of randomized clinical trials. 
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As regards the safety profile is currently difficult to assert 
the superiority of dexamethasone than other 
corticosteroids [13]. The greater efficacy and lower 
incidence of collateral effects lie in the lower 
dexamethasone lipophilicity compared to triamcinolone 
and fluocinolone. This data is in agreement with our 
observations during the follow-up. Furthermore, none of 
the three observed cases shows increases in IOP.  
 
Conclusion  
In the present series, Dex Implant was able to control  
and improve CME in 3 eyes of 3 patients of VKH 
syndrom [14-19]. The duration of effect of the implant 
was 4 to 6 months. No patients developed major systemic 
or ocular side effects, particularly ocular hypertension. In 
only one eye required surgical intervention,  for cataract 
progression that was already present at baseline. 
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